

Patent
Attorney Docket: 270/228

Sub
B2 Cs

an inhibitory polynucleotide comprising an antisense sequence of at least 40 nucleotides that specifically hybridizes sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1) and that inhibits expression of Repro-PC-1.0 in cells.

A marked-up version of the claims as amended are attached hereto as Appendix "A".

Regarding the species election, Applicants elect the polynucleotide encoding a Repro-PC-1.0 polypeptide. Claims 39, 40, 42, 43, 44, 45, 48, each read on this species.

Respectfully submitted.

LYON & LYON LLP

Dated: February 11, 2002

By: 

Kurt T. Mulville
Reg. No. 37,194

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600

Patent
Attorney Docket: 270/228

APPENDIX "A"
MARKED-UP VERSION OF CLAIMS
AFTER RESPONSE TO RESTRICTION REQUIREMENT
U.S. SERIAL NO. 09/680,121, FILED OCTOBER 4, 2000

39. A recombinant polynucleotide comprising a nucleotide sequence encoding at least 72 consecutive amino acids from Repro-PC-1.0 polypeptide (SEQ ID NO:2).

40. The polynucleotide of claim 39 wherein the nucleotide sequence encodes native Repro-PC-1.0 polypeptide (SEQ ID NO:2).

41. (Cancelled). [The polynucleotide of claim 39 wherein the nucleotide sequence encodes a Repro-PC-1.0 polypeptide analog.]

42. (Amended) The polynucleotide of claim 39 [41] wherein the nucleotide sequence encodes an immunogenic Repro-PC-1.0 polypeptide[analog].

43. A polynucleotide probe or primer of at least 40 nucleotides that specifically hybridizes to a nucleotide sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1) or its complement.

44. The polynucleotide probe or primer of claim 43 whose sequence is identical or complementary to a nucleotide sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1) or its complement.

45. The polynucleotide probe of claim 43 further comprising a label.

46. (Cancelled) [An inhibitory polynucleotide comprising an antisense sequence of at least 40 nucleotides that specifically hybridizes to a nucleotide sequence selected from Repro-PC-1.0 cDNA of SEQ ID NO:1 and that inhibits expression of Repro-PC-1.0 in cells.]

47. (Cancelled) [The inhibitory polynucleotide of claim 46 whose sequence is complementary to a nucleotide sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1).]

48. (Amended) A recombinant polynucleotide comprising an expression control sequence operably linked to a nucleotide sequence encoding:

Patent
Attorney Docket: 270/228

a Repro-PC-1.0 polypeptide,

[a Repro-PC-1.0 analog,]

a polynucleotide probe or primer of at least 40 nucleotides that specifically hybridizes to a nucleotide sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1) or its complement, or

an inhibitory polynucleotide comprising an antisense sequence of at least 40 nucleotides that specifically hybridizes sequence selected from Repro-PC-1.0 cDNA (SEQ ID NO:1) and that inhibits expression of Repro-PC-1.0 in cells.

49. A recombinant cell comprising a recombinant polynucleotide of claim 48.

50. A polynucleotide comprising at least 40 consecutive nucleotides of SEQ ID NO:1.

51. (Cancelled) [A Repro-PC-1.0 polypeptide analog that is not naturally occurring and that comprises a sequence of at least 100 consecutive amino acids selected from the amino acid sequence of Repro-PC-1.0 polypeptide (SEQ ID NO:2).]

52. (Cancelled) [The Repro-PC-1.0 polypeptide analog of claim 51 which is a decoy that competes with Repro-PC-1.0 polypeptides for interaction with molecules that naturally interact with Repro-PC-1.0.]

53. (Cancelled) [The Repro-PC-1.0 polypeptide analog of claim 51 which, when presented as an immunogen, elicits the production of an antibody which specifically binds to native Repro-PC-1.0 polypeptide.]

54. (Cancelled) [A polypeptide or polynucleotide vaccine for eliciting an immune response against Repro-PC-1.0 polypeptide analog or a polynucleotide encoding the analog.]

55. (Cancelled) [The vaccine of claim 54 wherein the analog bears an MHC Class I or MHC Class II binding motif.]

56. A polynucleotide comprising a nucleotide sequence encoding at least 100 consecutive amino acids from the polypeptide of SEQ ID NO:2.